Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Monopar Therapeutics Inc. - Common Stock
(NQ:
MNPR
)
69.07
-0.53 (-0.76%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Monopar Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
October 28, 2024
Via
Benzinga
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
↗
October 28, 2024
Via
Benzinga
MarketBeat Week in Review – 10/21- 10/25
October 26, 2024
Equities had a mixed week, but the tech-heavy NASDAQ powered to an all-time high; big tech earnings and key economic reports could bring more volatility
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Stocks
12 Health Care Stocks Moving In Friday's Intraday Session
↗
October 25, 2024
Via
Benzinga
What's Going On With Monopar Therapeutics Shares Friday?
↗
October 25, 2024
Monopar entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 for Wilson disease.
Via
Benzinga
Monopar Therapeutics Skyrockets 400% on Licensing Deal
October 25, 2024
Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug.
Via
MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
October 25, 2024
Via
Benzinga
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
↗
October 25, 2024
Via
Benzinga
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
↗
October 24, 2024
The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36.
Via
Benzinga
Topics
Stocks
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
↗
October 24, 2024
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder.
Via
Benzinga
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
October 24, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
October 22, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
October 15, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
October 07, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 01, 2024
Via
Benzinga
Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today
↗
September 12, 2024
Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans.
Via
Benzinga
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
September 12, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
August 27, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
August 21, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
August 14, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024
↗
August 09, 2024
MNPR stock results show that Monopar Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
August 09, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
August 09, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
July 09, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
June 25, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
↗
June 24, 2024
Via
Benzinga
Monopar and NorthStar Amend & Extend Collaboration
June 11, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
June 10, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
June 07, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
